As of December 31, 2023, Arena had cash, cash equivalents and restricted cash and investments of 300 $50,700,000 compared to $389,400,000 at December 31, 2022. The decrease is primarily related to the continued investment in commercialization activities and post approval commitments of our approved drug Loop Kindness, inventory purchases, advancement of our pipeline and mono plan payments, partially offset by an increase in cash receipts from sales of Loop Kindness. Total net revenue increased 59 percent to $45,100,000 for the 4th quarter compared to the prior year period of $28,400,000 Total net revenue for the year was $175,500,000 an increase of over 31% over the prior year of $134,000,000 Total net product revenue increased 49 percent to $42,300,000 for the 4th quarter Compared to the prior year period of $28,400,000 total net product revenue was $158,500,000 $103,500,000 for the years ended December 1, 2023 and 2022. The increase in both periods is primarily due to an increase from our 2 main customers for the Kindness sales, driven predominantly by further penetration of the LN market. License collaboration and royalty revenue was $2,800,000 for the 4th quarter compared to the prior year period of $109,000 License collaboration and royalty revenue was $17,000,000 30 point $6,000,000 for the years ended December 31, 2023, 2022 respectively.